SynthesisAmerican journal of Alzheimer's disease and other dementias2014
Pharmacological treatments for frontotemporal dementias: a systematic review of randomized controlled trials.
Synthesis in American journal of Alzheimer's disease and other dementias, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 41 citations in OpenAlex.
- Comorbidity Between Anti-GAD65 Autoimmune Encephalitis and Behavioral Variant Frontotemporal Dementia: A Case Report.Reports (MDPI) · 2026Article
- Pharmacological management in frontotemporal dementia and patient outcomes: a retrospective cohort study using the TriNetX platform.Frontiers in neurology · 2026Article
- Article
- Striatal dopaminergic patterns and clinical features in frontotemporal dementia.Brain communications · 2025Article
- Functional Disabilities and Psychiatric Symptoms in Primary Progressive Aphasia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2022Article
- Rehabilitation in Dementia.Indian journal of psychological medicine · 2021Article
- Management of Behavioral and Psychological Symptoms of Dementia.Current psychiatry reports · 2019Review
- Repetitive transcranial magnetic stimulation for the treatment of cognitive impairment in frontotemporal dementia: an open-label pilot study.Neuropsychiatric disease and treatment · 2018Article
- Atypical parkinsonian syndromes: a general neurologist's perspective.European journal of neurology · 2018Review
- Oxytocin for frontotemporal dementia: a systematic review.Therapeutic advances in psychopharmacology · 2017Review
- The behavioural variant frontotemporal dementia (bvFTD) syndrome in psychiatry.Journal of neurology, neurosurgery, and psychiatry · 2016Review
- Memantine for the treatment of frontotemporal dementia: a meta-analysis.Neuropsychiatric disease and treatment · 2015Article
- Frontotemporal dementia: diagnosis, deficits and management.Neurodegenerative disease management · 2014Review
- Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes.Translational neurodegeneration · 2014Review
- Utilization of transcranial direct current stimulation for neuromodulation in frontotemporal dementia.Industrial psychiatry journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this review is to summarize the current data on the pharmacological treatments for frontotemporal dementias from randomized controlled trials. A systematic search of 4 major databases, PubMed, Medline, PsychINFO and Cochrane, found a total of 9 randomized controlled, double-blinded clinical trials. Of these, 2 trials used the selective serotonin reuptake inhibitor (SSRI), paroxetine; 1 trial used trazodone; 2 trials used stimulants (methylphenidate and dextroamphetamine); 1 trial used the acetylcholinesterase inhibitor, galantamine; 2 trials used the N-methyl-d-aspartate antagonist, memantine; and 1 trial used the neuropeptide oxytocin. The analysis of the available data indicates that SSRIs, trazodone, and the amphetamines may be effective in reducing some behavioral symptoms, but none of these medications had an impact on cognition. Available data indicate that these medications were well tolerated in all the trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.